The Effects of Glucagon on Hepatic Metabolism
Launched by ADRIAN VELLA · Aug 11, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how glucagon, a hormone that helps control blood sugar levels, affects the way the liver processes certain nutrients in people with obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Researchers want to understand if problems with how glucagon works in the body are linked to factors like obesity and liver fat, especially in people who are lean versus those who are overweight. The goal is to learn more about how glucagon influences liver metabolism, which could help in developing better treatments for these conditions.
If you are interested in participating, you should be between the ages of 18 and 75, be willing to take part, and be able to give consent. However, certain medical conditions—like having had previous upper abdominal surgery, active diseases, or issues that might affect MRI results—may exclude you from joining. Participants will undergo tests to see how glucagon affects their liver and metabolism, contributing to a better understanding of these conditions. This study is currently recruiting, and it's a chance to help advance medical knowledge while receiving thorough evaluations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willing to participate
- • Able to give consent
- Exclusion Criteria:
- • History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
- • Active systemic illness or malignancy.
- • Symptomatic macrovascular or microvascular disease.
- • Contraindications to MRI (e.g. metal implants, claustrophobia).
- • Hematocrit \< 35%
- • TSH \< 0.4 or \> 5.5.
- • Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire
About Adrian Vella
Adrian Vella is a distinguished clinical trial sponsor known for his commitment to advancing medical research and innovation. With a strong background in endocrinology and metabolic diseases, Dr. Vella leads initiatives that focus on understanding and developing therapeutic interventions for conditions such as diabetes and obesity. His expertise encompasses the design and execution of clinical studies, ensuring adherence to regulatory standards and ethical guidelines. Through collaborative efforts with academic institutions and industry partners, Adrian Vella aims to translate scientific discoveries into effective treatments that improve patient outcomes and enhance healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Adrian Vella
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials